培训课件--科素亚降低脑卒中的优势.pptVIP

* * Slide 14 LIFE: 降压效果相似 氯沙坦与阿替洛尔组的降压效果相似21 随访期的BP测量结果如幻灯片所示。 在随访期末或主要终点发生前的末次随访时，氯沙坦和阿替洛尔组的血压均显著降低 (氯沙坦组为–30.2/–16.6 mmHg; 阿替洛尔组为–29.1/–16.8 mmHg)。两组的坐位收缩压与基线相比均显著降低 (p=0.017)21 最后一次随访时的平均血压氯沙坦组为144.1/81.3 mmHg ，阿替洛尔组为145.4/80.9 mmHg，平均动脉压分别为 102.2和 102.4 mmHg，均无显著差异 21 氯沙坦组和阿替洛尔组目标血压 ?140/90 mmHg的患者比例分别为49% 和 46% 21 始终采用研究药物治疗直至研究结束的患者氯沙坦和阿替洛尔的平均使用剂量分别为82 mg/d和79 mg/d21 SOURCE: 5-05 CZR 2003-W-6953-SS (slide 17) Ref 21, p 997, Table 1 (n’s); p 998, C2, ?2, L_, Fig 3 Ref 21, p 1000, C1, ?3, L9-12 Ref 21, p 998, C2, ?2, L11-19 Ref 21, p 999, C1, L1-5 Ref 21, p 999, C1, ?1, L1-3 Ref 21, p 998, C2, ?2, L9-11 * Slide 16: LIIFE: Primary Composite Endpoint For the first time ever a combined cardiovascular morbidity and mortality primary endpoint trial in hypertensive patients has demonstrated the superiority of an antihypertensive agent, losartan, over an active comparator that is a current standard treatment for hypertension (atenolol).1 The primary endpoint of LIIFE was the composite of cardiovascular morbidity and mortality (defined as stroke, MI, and cardiovascular death.) By adjusted intention-to-treat analysis (which was the primary analysis approach of this study), losartan was superior to atenolol in reducing the risk of combined cardiovascular morbidity and mortality – a significant 13% relative risk reduction vs. atenolol (p=0.021).1 The primary result was even stronger, 14.6% (p=0.009), if not adjusted for Framingham risk score and ECG-LVH at baseline.1 No significant differences in CV death and MI vs. atenolol were observed.1 The risk reduction in CV events with atenolol was consistent with those in previous studies with beta blocker-based regimens vs. placebo, such as the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension).12 The superior risk reduction in the primary endpoint (composite of CV death, MI, and stroke) with losartan vs. atenolol in the LIIFE study suggests an important role for losartan in patient